Table 1.

Correlations of SPARC methylation with clinical characteristics of pancreatic cancer

Clinical characteristics	Cases (n = 40)	Methylation ratio (%)
		Region 1	p	Region 2	p	Total	p
Gender
Male	25	58.6 ± 11.8	0.709	53.6 ± 18.7	0.265	56.5 ± 11.9	0.337
Female	15	59.8 ± 12.1		55.5 ± 22.6		58.0 ± 13.2
Age (yrs)
≤ 55	19	58.0 ± 12.0	0.386	52.6 ± 19.1	0.156	55.7 ± 12.1	0.142
> 55	21	60.0 ± 11.7		56.0 ± 21.0		58.3 ± 12.6
Alcohol
--	20	58.7 ± 12.9	0.794	46.6 ± 18.2	0.016	53.7 ± 11.2	0.154
+	20	60.0 ± 11.7		62.1 ± 19.1		60.5 ± 12.6
Smoking
--	22	58.1 ± 13.7	0.671	47.5 ± 17.5	0.017	53.7 ± 11.9	0.067
+	18	60.2 ± 9.1		62.8 ± 19.1		61.3 ± 11.7
Tumor size (cm)
≤ 2	21	55.4 ± 10.5	0.087	46.1 ± 18.8	0.029	51.5 ± 10.1	0.013
> 2	19	63.1 ± 12.0		63.5 ± 17.4		63.3 ± 11.7
Differentiation
Moderate	19	59.6 ± 12.2	0.625	53.6 ± 20.4	0.799	57.1 ± 12.4	0.877
Poor	21	58.6 ± 11.6		55.0 ± 20.1		57.1 ± 12.5
Lymph node metastasis
--	23	60.4 ± 12.4	0.307	53.7 ± 20.0	0.832	57.6 ± 12.5	0.421
+	17	57.2 ± 10.9		55.2 ± 20.7		56.4 ± 12.3
pTNM stage
I+II	21	58.2 ± 12.4	0.444	51.9 ± 20.1	0.867	55.5 ± 12.6	0.543
III+IV	19	60.0 ± 11.2		57.1 ± 20.0		58.8 ± 12.0

Correlations of SPARC methylation with clinical characteristics of pancreatic cancer were determined by general linear model univariate analysis.